Get Updates

Research & Clinical Trials

FORCE has a strong commitment to promoting research to benefit our community. We advocate for more research funding, educate people about available studies, and report findings back to our community.

| More

Featured Research

For a listing of other research studies recruiting patients please visit our Active Studies page.

QUADRA
QUADRA

A study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least 3 previous chemotherapy regimens (which may have included a PARP inhibitor).

ARIEL2
ARIEL2

ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer.

OlympiAD
OlympiAD

A phase III study comparing the PARP inhibitor olaparib to standard chemotherapy in patients with HER2 negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation

EMBRACA
EMBRACA

BioMarin is enrolling EMBRACA, a Phase 3 study of talazoparib, a PARP inhibitor, in patients with locally advanced and/or metastatic BRCA+ breast cancer: www.embracastudy.com

Survey on risk reduction options for BRCA1 or BRCA2 positive women
Survey on risk reduction options for BRCA1 or BRCA2 positive women

If you are a woman with a BRCA mutation, please complete this 45-minute online survey to help researchers understand how you think about treatments to reduce your risk of developing breast and ovarian cancer.

BRAVO
BRAVO

A study investigating the PARP inhibitor niraparib for women with previously treated HER2 negative, BRCA positive breast cancer.

ABOUT Patient Powered Research Network
ABOUT Patient Powered Research Network

The ABOUT Network is the first-ever patient-powered research registry created and governed by and for people affected by HBOC.

Basser Research Center for BRCA
Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.

ARIEL 3
ARIEL 3

ARIEL3 is a Phase 3 study comparing the effects of the PARP inhibitor, rucaparib, versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

FORCE Research Surveys
FORCE Research Surveys

FORCE conducts surveys to better understand and address the needs of our community. By participating, you can help advance hereditary breast and ovarian cancer research.

Salpingectomy Research Registry
Salpingectomy Research Registry

Study for women who have had their fallopian tubes surgically removed and kept one or both of your ovaries to reduce their ovarian cancer risk.

INFORM Study
INFORM Study

A study for newly-diagnosed breast cancer patients who carry a BRCA1 or BRCA2 mutation.

QUADRA QUADRA

QUADRA is a study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least 3 previous chemotherapy regimens (which may have included a PARP inhibitor). The study will evaluate the antitumor activity of niraparib (an oral PARP inhibitor).  Women with and without germline BRCA mutations can participate, and testing will be done as part of the study.   All participants will receive niraparib.  

For more information visit:

www.tesarobio.com or Clinicaltrials.gov

More Information

ARIEL2 ARIEL2

ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer.  ARIEL2 is now enrolling its expansion phase to include patients who have failed three lines of prior chemotherapy and are platinum sensitive ore platinum resistant.  All patients enrolled in the study will receive the PARP inhibitor rucaparib.

More Information

OlympiAD OlympiAD

OlympiAD is a phase III study comparing how olaparib (a PARP inhibitor) works compared to standard chemotherapy in  patients with HER2 negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation.  Patients will be randomised 2 to 1, so patients will be twice as likely to receive olaparib than standard chemotherapy. Patients who may be eligible for the study but do not know their BRCA mutation status will be tested at no expense.

More Information

EMBRACA EMBRACA

BioMarin is enrolling EMBRACA, a Phase 3 study of talazoparib, an oral PARP inhibitor, in people with locally advanced and/or metastatic BRCA+ breast cancer. Two-thirds of study participants will be randomly selected to receive talazoparib and one-third will receive single-agent chemotherapy. All study-related medication and care will be provided, including a genetic test for BRCA mutation for those who qualify and have not yet been tested. 

More Information

Survey on risk reduction options for BRCA1 or BRCA2 positive women Survey on risk reduction options for BRCA1 or BRCA2 positive women

RTI International, a non-profit research organization, is recruiting women to participate in an opinion survey. The survey will ask you questions about your experience living with a BRCA1 or BRCA2 mutation, and your opinions about current and potential treatments that can reduce the risk of developing breast or ovarian cancers.

To help with this research, please use the link below to take this survey. The survey is open to women who have tested positive for a mutation in BRCA1 or BRCA2 genes, age 25-55, with no previous diagnosis of breast or ovarian cancer.

More Information

BRAVO BRAVO

BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive (hereditary) breast cancer that has progressed after previous treatment. The study will look at how well niraparib (a PARP inhibitor) works compared with standard chemotherapy. Patients will be randomized 2 to 1 so that two patients will take niraparib and one will take their doctor’s choice of chemotherapy. Collaborators for this international trial include the Breast International Group (BIG) and the European Organisation for Research and Treatment of Cancer (EORTC).

Visit clinicaltrials.gov at: http://clinicaltrials.gov/ct2/show/NCT01905592 or http://www.tesarobio.com


 

More Information

ABOUT Patient Powered Research Network ABOUT Patient Powered Research Network

ABOUT is the first ever research registry created and governed byand for people affected by HBOC. The ABOUT Network is a "patient-powered" research registry and one of only 29 networks chosen for participation in the National Patient Centered Outcomes Research Network (known as PCORnet). Our goal is to enroll as many Americans with HBOC as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

More Information

Basser Research Center for BRCA Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center. 

More Information

ARIEL 3 ARIEL 3

ARIEL3 is a Phase 3 study comparing the effects of the PARP inhibitor, rucaparib, versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer. Two thirds of the participants enrolled in this study will receive rucaparib. The other third of participants will receive placebo.  If you qualify for the ARIEL3 trial, you will receive the following as part of the study: study-related physical exams, lab tests results including BRCA and the biomarker test results, the study medication (rucaparib) or placebo.
 

More Information

FORCE Research Surveys FORCE Research Surveys

FORCE conducts surveys and partners with researchers who conduct surveys to better understand and address the needs of our community. By participating in surveys for which you are eligible, you help promote and advance hereditary breast and ovarian cancer research.

More Information

Salpingectomy Research Registry Salpingectomy Research Registry

Have you had your fallopian tubes surgically removed and kept one or both of your ovaries? Did you have this surgery to reduce your ovarian cancer risk? Researchers at the University of Washington in collaboration with Facing Our Risk of Cancer Empowered (FORCE) are studying the long-term outcomes of prophylactic salpingectomy (removal of the fallopian tubes). To learn more about this research study, call 206-685-7927 or email vhy@uw.edu orkagnew@uw.edu. They cannot ensure the confidentiality of any information sent by e-mail.

More Information

INFORM Study INFORM Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited abnormality (mutation) in one of the breast cancer genes, BRCA1 or BRCA2. 

More Information

Learn about the latest breakthroughs in research and our ABOUT Network.

Featured Research

With input from our Scientific Advisory Board, FORCE critically evaluates new research articles on topics of interest to our community and makes the science understandable and accessible to our community.

Join the ABOUT Network

The goal of the ABOUT network is to enroll as many Americans with HBOC risk as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

FORCE:Facing Our Risk of Cancer Empowered